Skip to main content
SpringerLink
Log in

Head-to-Head Intervention Trials in Hypertension

After the Gold Rush

  • Editorial
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT study group. Lancet 1998; 351: 1755–62

    Article  PubMed  CAS  Google Scholar 

  2. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6

    Article  PubMed  CAS  Google Scholar 

  3. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs on cardiovascular mortality and morbidity in elderly patients with hypertension: the Swedish Trial in Old Patients with Hypertension-2 (STOP-2). Lancet 1999; 354: 1751–6

    Article  PubMed  CAS  Google Scholar 

  4. Bertram P, Poole-Wilson PA, Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: a randomized trial: The Losartan Heart Failure Survival Study (ELITE II) investigators. Lancet 2000; 355: 1582–7

    Article  Google Scholar 

  5. Yusuf S, Sleight P, Dagenais G, et al. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: Heart Outcomes Prevention Evaluation (HOPE) study group. N Engl J Med 2000; 342: 145–53

    Article  PubMed  CAS  Google Scholar 

  6. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356(9227): 366–72

    Article  PubMed  CAS  Google Scholar 

  7. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356(9227): 359–65

    Article  PubMed  CAS  Google Scholar 

  8. PROGRESS Collaborative Group. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41

    Google Scholar 

  9. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). N Engl J Med 2001; 345: 851–60

    Article  PubMed  CAS  Google Scholar 

  10. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes: Irbesartan in Patients with type 2 Diabetes and Microalbuminuria study group. N Engl J Med 2001; 345: 870–8

    Article  PubMed  CAS  Google Scholar 

  11. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003

    Article  PubMed  CAS  Google Scholar 

  12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97

    Google Scholar 

  13. Wing L, Reid C, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583–92

    Article  PubMed  CAS  Google Scholar 

  14. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study): EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) investigators. Lancet 2003; 362(9386): 782–8

    Article  PubMed  CAS  Google Scholar 

  15. Pfeffer MA, McMurray J, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: Valsartan in Acute Myocardial Infarction Trial (VALIANT) investigators. N Engl J Med 2003; 349: 1893–906

    Article  PubMed  CAS  Google Scholar 

  16. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial: SCOPE study group. J Hypertens 2003; 21(5): 875–86

    Article  PubMed  CAS  Google Scholar 

  17. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–31

    Article  PubMed  CAS  Google Scholar 

  18. Chobanian A, Bakris G, Black H, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–71

    Article  PubMed  CAS  Google Scholar 

  19. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53

    Google Scholar 

  20. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363(9426): 2049–51

    Article  PubMed  CAS  Google Scholar 

  21. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562–71

    Google Scholar 

  22. Brenner BM, Cooper ME, de Zeeuw D, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003; 26: 683–7

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Cardiology, II Faculty of Medicine, University of Rome “La Sapienza”, Sant’Andrea Hospital, Via di Grottarossa, Rome, 1035-39, 00189, Italy

    Massimo Volpe

  2. IRCCS Neuromed, Pozzilli (IS), Italy

    Massimo Volpe

Authors
  1. Massimo Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Volpe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volpe, M. Head-to-Head Intervention Trials in Hypertension. High Blood Press Cardiovasc Prev 12, 1–4 (2005). https://doi.org/10.2165/00151642-200512010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151642-200512010-00001

Search

Navigation